Financial StabilityGalectin's cash runway extends beyond the key data readout, providing financial flexibility before advancing belapectin into Phase 3.
Trial DesignThe revised trial design for belapectin's Phase 2b study increases the likelihood of success, as it now has a lower statistical hurdle to meet.
Trial EnrollmentThe NAVIGATE trial was over-enrolled by 42 patients, reflecting positive investigator response and potentially enhancing the trial's statistical power.